Breast Cancer

The combination of letrozole, everolimus, and trastuzumab is well tolerated with encouraging clinical activity in heavily pretreated patients with HER2-amplified or mutant advanced breast cancer. Read More ›

The clinical trial design was presented of a single-center, phase 2 study of GDC-0084, a brain-penetrant inhibitor of class I PI3K and mTOR, to evaluate the efficacy of GDC-0084 plus trastuzumab for the treatment of central nervous system metastases in patients with HER2+ breast cancer. Read More ›

Results from the FeDeriCa study showed that a novel subcutaneous fixed-dose formulation of pertuzumab + trastuzumab demonstrated pharmacokinetics, efficacy, and safety comparable to intravenous pertuzumab + trastuzumab (each + chemotherapy) in patients with HER2+ breast cancer. Read More ›

Real-world practice patterns regarding the use of trastuzumab emtansine as adjuvant therapy in HER2+ early breast cancer were significantly changed after presentation and publication of the results from the phase 3 KATHERINE study. Read More ›

The study design is described as an ongoing phase 3 clinical study of tucatinib plus ado-trastuzumab emtansine (T-DM1) in patients with unresectable locally advanced or metastatic HER2+ breast cancer. Read More ›

OS (overall survival) data favored margetuximab plus chemotherapy compared with trastuzumab plus chemotherapy in patients with metastatic breast cancer (MBC) in the SOPHIA study; however, the data did not reach statistical significance at a second interim analysis after 270 events. Read More ›

The ATEMPT trial results demonstrated that in patients with stage I HER2+ breast cancer, adjuvant trastuzumab emtansine monotherapy failed to demonstrate the prespecified reduction in clinically relevant toxicities compared with trastuzumab. Read More ›

ARX788, an antibody-drug conjugate of anti-HER2 monoclonal antibody linked to a tubulin inhibitor, was shown to be well tolerated in heavily pretreated patients with HER2+ metastatic breast cancer, without evidence of grade ≥3 pneumonitis, and an encouraging overall response rate in the 1.3-mg/kg every-3-weeks cohort. Read More ›

The combination of ruxolitinib and trastuzumab without chemotherapy was well tolerated but failed to demonstrate improved progression-free survival compared with historical controls in patients with HER2+ metastatic breast cancer. Read More ›

Results of the phase 3 HER2CLIMB study show that in patients with HER2+ metastatic breast cancer with and without brain metastases, the combination of tucatinib with capecitabine and trastuzumab significantly improves survival and could become a new standard of care. Read More ›

Page 2 of 8

Subscribe to
Oncology Practice Management

Stay up to date with oncology news & updates by subscribing to recieve the free OPM print publications or weekly e‑Newsletter.

I'd like to recieve: